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A multiplexed biophotonic assay platform has been developed using the localised particle 
plasmon in gold nanoparticles assembled in an array and functionalised for two assays: total 
IgG and C-reactive protein (CRP). A protein A/G (PAG) assay, calibrated with a NIST 
reference material, shows a maximum surface coverage of max = 7.13 ± 0.19 mRIU, 
equivalent to 1.5 ng mm-2 of F(ab)-presenting antibody. The CRP capture antibody has an 
equivalent surface binding density of max = 2.95 ± 0.41 mRIU indicating a 41% capture 
antibody availability. Free PAG binding to the functionalised anti-CRP surface shows that 
only 47 ± 3 % of CRP capture antibodies are correctly presenting Fab regions for antigen 
capture. The accuracy and precision of the CRP sensor assay was assessed with 54 blood 
samples containing spiked CRP in the range 2 – 160 mg/L. The mean accuracy was 0.42 mg/L 
with Confidence Interval (CI) at 95% from -14.7 to 13.8 mg/L and the precision had a 
Coefficient of Variation (CV) of 10.6% with 95% CI 0.9% - 20.2%. These biophotonic platform 
performance metrics indicate a CRP assay with 2 - 160 mg/L dynamic range, performed in 8 






Novel biosensor events are often reported demonstrating a transduction of a detection 
event specific to a molecule of interest, usually under ideal conditions 1-5. Less often, 
biosensors are put through an analysis of sensitivity and specificity to establish the accurate 
detection of the target molecule in biologically or environmentally relevant fluids 6-8. Fewer 
biosensors still are then tested against other platforms and international standards to make 
the transition from technique to technology: no molecular biosensor based diagnostic 
devices received FDA 510(k) approval in the period 2018 to April 2019 9. In part, the reason 
is because the clinically relevant accuracy and precision requirements demand technique 
fidelity that can be mass produced. The majority of the surviving technologies in the clinical 
chemistry laboratories in the EU are dominated by a few large-scale devices such as Roche 
Cobas, Abbott and Hitachi, all using a turbidimetric detection method. Curiously, circulating 
standards such as the RIQAS provided by Randox suggest there is significant variation in the 
accuracy of these techniques, presumably based on their chosen reference standards. The 
instruments and their underlying techniques are robust but require sample preparation 
such as clotting and consequently trained operators.  
 
New techniques must also meet the precision and accuracy requirements to become 
clinically useful which places significant demands on the reproducible construction of sensor 
surfaces such as the orientation of antibodies 10 and their durability over the cycles of 
precision and accuracy testing. Our biophotonic biosensor platform uses gold nanoparticles 
printed into a 150-element array as seeds, grown into larger scatter centres and 
functionalised with different antibodies to allow multiplexed analyte analysis, Figure 1. A 
two-step sandwich assay provides sensitivity and specificity to the target analyte and video 
capture of the array spot brightness changes produces an immuno-kinetic assay with results 
in 8 minutes. The conversion to array reading technique into a technology requires the 
sensor platform to be robust in complex, biologically relevant media11-18 with patient-to-
patient variability whilst preserving the accuracy and precision needed for regulatory 




Figure 1 The biophotonic multiplexed array immuno-kinetic assay platform for total IgG and CRP analysis. There are three 
stages to the assay: capture of the analyte from the diluted bio-sample using PAG and aCRP; a wash step; and  a detection 
step with a known concentration of aCRP, producing an evolving area-under-the curve for calibration.  
 
Manufacture under regulatory control and subsequent production requires a set of quality 
control (QC) metrics defining the figures-of-merit of the assay that can be monitored during 
batch production. The assay platform has been optimised for two assays, C-reactive protein 
(CRP) and total IgG both have commercial interest. Total IgG provides useful information 
about antibody integrity19 and in-line QC of the materials on delivery supporting both the 
CRP assay and the total IgG assay.  CRP is the target clinical assay and is the subject of 
~5,000 publications per year (PubMed) as a sensitive but not specific biomarker of systemic 
inflammation in many conditions such as sepsis20. CRP has an important potential role in 
antibiotics stewardship providing a test before antibiotics are prescribed, despite its lack of 
specificity at low values is it useful in respiratory tract infections (RTI).21-23 Patients recruited 
to the RTI cohort by the GP with CRP less than 20 mg/L are likely to be self-resolving, 20-100 
mg/L watch and wait and at 100 mg/L or more are prescribed antibiotics24. Antibiotic 
 5 
stewardship with these guidelines reduces the use of antibiotics up to 35% and improves 
the diagnostics accuracy from 70% to 95%. The use-case required clinically sets an accuracy 
standard.  
 
Incorporating a CRP test into a care pathway and achieving clinical adoption requires 
regulatory approval: ISO 13485 leading to a CE mark in the EU or FDA approval in the US. 
Only the FDA sets explicit targets for the performance criteria of CRP assays based on the 
accuracy and precision over the specified range of intended use aligned with clinical utility 
25.  Precision is well defined with intra-day and inter-day measures but accuracy is not: there 
is no internationally agreed CRP standard material adopted by all laboratories or 
manufacturers. The non-standardised accuracy implies that measurements in different 
hospitals are providing differences in accuracy as large as 20% which around a clinical 
decision point of 100 mg/L constitutes an error of 80 mg/L and 120 mg/L leading to regional 
differences in care pathway decisions. The RTI care pathway requires accuracy at each of 
the CRP cut-off levels which influence the clinical decision and would therefore expect a 
circulating standard and international convention.  
 
Biosensors for CRP in primary or secondary care have a number of advantages: rapid 
delivery of the CRP test result; a large install base with a traceable accuracy standard; low 
blood sample volumes allow more frequent testing for trend analysis; and multiple testing 
provides a patient response profile rather than just a single measure – trend medicine. In 
this paper, we report the design and characterisation of a rapid CRP assay on a gold 
nanoparticle localised particle plasmon resonance array platform that address these 
advantages. The dynamic range and assay fabrication parameters are assessed along with 
the origins of the sensitivity. Finally, an accuracy and precision analysis was performed using 
a protocol, characterised against traceable reference materials, that is a potential first step 
in the evaluation of a technique on the journey to technology.  
 
Experimental Methods and Materials 
The CRP assay was performed on an in-house immuno-kinetic assay platform using sensing 
light scattering from an array of bio-functionalised gold nanoparticles; Light Scattering Array 
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Reader (LiScAR), a benchtop device described in detail elsewhere 13-15, 26-28. Briefly, ca. 3.5 
nm seed gold nanoparticles are deposited with sciFLEXARRAYER S3 spotter (Scienion AG, 
Berlin) into an array of typically 150 elements. The arrays are removed from the printer and 
placed in a growth solution that develops the seed nanoparticles into truncated icosahedra 
with a diameter of approximately 60 nm. The localised particle plasmon field has a 
penetration depth of 63 nm 16, consequently the light scattering properties are sensitive to 
the refractive index local to the nanoparticle surface. The nanoparticles are functionalised 
with a self-assembled monolayer 13, 28 to allow EDC-NHS coupling of biomolecules to the 
surface. The array is returned to the printer for functionalisation with the target assays: 
protein A/G (PAG) for total IgG detection, anti-CRP for CRP detection and a set of control 
spots functionalised with BSA or FBR to correct for variations in temperature, non-specific 
binding and variations in the illumination field. The arrays are illuminated in total-internal-
reflection and imaged normal to the sensor surface with a video camera: the change in 
scattered light from the array elements is associated with increasing mass (local refractive 
index or relative permittivity) in the plasmon field penetration depth. The brightness change 
is calibrated for refractive index sensitivity by providing a switch of known refractive index, 
PBS and 2PBS which corresponds to a refractive index change of 1.6 mRIU (measured with 
Reichert AR200 digital refractometer): the kinetic data are presented as plots of mRIU vs 
time.  
The immuno-kinetic assay is performed in three steps: (i) capture of the analyte from 
a diluted whole blood sample flowing over the surface; (ii) a running buffer wash step to 
remove the non-specifically bound material from the sensor surface; and (iii) an injection of 
detection antibody at fixed concentration, to complete a sandwich assay as shown in Figure 
1. The evolution of the signal brightness is corrected for temperature and illumination field 
variations using the control spots and integrated over 120 s in the detection step to produce 
an Area-Under-the-Curve (AUC). AUCs are collected for standard samples to produce a 
calibration curve which is used to derive the final unknown (blinded) analyte concentration. 
The sensor surface can be regenerated with a low pH buffer and may perform in excess of 
100 assays with limited degradation. Sets of 20 assays are profiled for mean variation in AUC 
for the CRP assay and show degradation of 5.8%, stable over multiple repeats. The protein 
A/G surface density is calibrated using the NIST reference antibody (RM 8671) to produce 
calibrated binding site density 29.  
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Antibody binding on PAG via the Fc region presents the Fab region to the solution to 
bind the target analyte. EDC-NHS coupling of antibodies to the surface does not preserve 
orientation (or activity). However, the antibody orientation on the sensor surface can be 
interrogated using an Fc-presenting assay by passing PAG over the surface. The surface 
density and orientation of antibodies produce a measure of quality control in the 
manufacture of the assay arrays19.  
The kinetic analysis of the assay response is performed using experimental data 
obtained from a range of low protein concentration samples to produce an accurate 
assessment of the Langmuir adsorption kinetic parameters derived from a simultaneous, 
global fit to the complete kinetic dataset 17. The total bound protein surface density is 
characterised by max derived from the global fit - a measure of the total surface capacity 
which can be calibrated using a NIST standard material and compared with the theoretical 
predictions.  
A reference CRP assay dataset was collected using the Alere Afinion CRP laboratory 




The materials used in the course of the experiments were used without further purification, 
as certified by the suppliers. Sigma-Aldrich supplied phosphate buffered saline in tablet 
form (Sigma, P4417), phosphoric acid solution (85±1 wt. % in water, batch W290017, Sigma 
345245), Tween 20 (Sigma, P1379), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (commercial grade, E7750), N-hydroxysuccinimide (98%, 130672) and bovine 
serum albumin (>98%, A3059). SAM molecules, linker HS-C11-EG6-OCH2-COOH (>95%, TH 
003-M11.N6) and spacer HS-C11-EG3-OH (>95%, TH 001-M11.N3), were supplied by 
ProChimia Surfaces. Blood media (whole blood, Na-citrate, EDTA and heparin tubes) were 
supplied by Cambridge Bioscience Ltd. Native human C-reactive protein (>99%,  1mg/mL 
and 0.09% sodium azide BioRad PHP277) and goat anti human CRP polyclonal antibody 
(BioRad 1707-0189G) were obtained from Bio-Rad. Recombinant PAG was supplied by 
ThermoFisher Scientific (21186). The assay running and dilution buffer was PBS with 0.005 
v/v % Tween 20 and the regeneration buffer was 0.1 M phosphoric acid solution in 
deionized water. Alere Afinion CRP tests were purchased from Abbott (1116522). A stock 
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solution of 320 mg/L CRP was made by adding 48 L of Biorad solution to 102 L of blood. 
Subsequent lower concentrations of CRP were made by serial dilutions of the 320 mg/L 
stock blood solution with pure blood. The CRP concentration in the Cambridge Blood Media 
as supplied was measured as less than 5 mg/L using an Alere Afinion AS100 device. 
Results 
The initial set of experiments characterised the CRP capture antibody both in purity, surface 
binding density and orientation on tethering to the sensor surface. The protein binding 
density was evaluated with two assays: the surface antibody coverage calibrated with the 
NIST antibody standard and the antibody orientation with the PAG-Fc presenting assay. The 
NIST reference antibody binding to the printed PAG surface is shown in Figure 2(A) at three 
concentrations and fitted to the Langmuir adsorption isotherm equation simultaneously for 
all three concentrations to derive the kinetic parameters: maximum surface load max, 
association rate constant ka and dissociation rate constant kd, presented in Table 1. The 
biophotonic CRP sensor was interrogated by first comparing the purity of the aCRP antibody 
material with the NIST antibody standard of known purity 96.6% 29 binding to the PAG. The 
observed aCRP load on PAG surface resulted in max = 2.95 ± 0.41 mRIU, compared with the 




Figure 2 aCRP antibody and NIST antibody standard binding kinetics: (A) NIST standard material (solid lines)  and aCRP 
antibody (dashed lines) binding to the PAG assay for 200 s followed by a running buffer wash  using a flow rate of 6 mL/hr 
(1, 5, 10 nM antibody samples in blue, black and red, from bottom to top); the arrows indicate the injection of aCRP and the 
onset of washing; B) PAG binding to the printed aCRP antibody assays a surface for available Fc binding sites (1, 2, 5, 10, 25 
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nM  PAG concentration samples from bottom to top), with the global fit to the data and plots of the fit residuals and their 
distribution  
The orientation of the aCRP printed to the CRP assay surface was determined using PAG in 
solution, flowing over five different concentration samples, Figure 2(B), from which the 
kinetic parameters were derived,  Table 1.  
 
Table 1 Binding Kinetic Parameters for PAG binding to Fc region on the CRP assay channel, CRP binding to the CRP assay 
Channel and aCRP binding to a PAG surface.  
Sample 
NIST Binding to 
PAG surface 
PAG-Fc Assay on 
aCRP surface 
CRP Binding to 
aCRP surface 
aCRP Binding to 
PAG surface 
max / mRIU 7.35 ± 0.09 0.10 ± 0.02 0.17 ± 0.01 2.95 ± 0.41 
ka (M-1-s-1) /105 2.14 ± 0.64 3.31 ± 0.14 23.0 ± 3.6 3.30 ± 0.71 
kd (s-1) /10-4 0.34 ± 0.88 7.72 ± 0.45 4.54 ± 13 0.1 (fixed) 
KD /nM 0.15 ± 0.41 2.34 ± 0.24 0.20 ± 0.60 0.03 
 
The quantitative CRP assay on the LiScAR platform is based on a calibration curve obtained 
by testing a set of standard samples over the dynamic range of the assay. The standards are 
prepared by spiking whole blood media with known concentration of CRP. The preparation 
volumetric accuracy was typically 5%, principally from pipetting errors. The spiked blood 
sample is flowed over the sensor surface for 120 s, the surface is then washed for 140 s and 
then the detection antibody at 100 nM is flowed for 120 s; integration over the detection 
step signal changes produces the AUC for the calibration curve in mRIU s. The same 
polyclonal antibody is used for both capture and detection. The AUC data obtained for CRP 
standard samples in the detection step, Figure 3A, were fitted to a five-parameter logistic 




Figure 3 CRP Immunoassay: (A) kinetic data featuring sample CRP (spiked CRP concentrations in blood were 320, 200, 107, 
36, 12, 3.9, 0.44, 1.3 mg/L from top to bottom) capture step from i to ii, a wash step of running buffer over the sensor from 
ii to iii, and subsequent binding of the detection a-CRP antibody from iii to iv – a 120s integration time; (B) fitting the 
integrated responses from the shaded area in panel A (circles) to a 5-parameter logistic function forms an assay calibration 
curve. 
In general, the systematic nonspecific binding and the observed signal noise level result in a 
two standard deviation limit of detection (LoD) equivalent to 0.4 mg/L CRP concentration in 
the sample before the 100-fold dilution employed in the assay protocol. The lower limit of 
quantification (LoQ), commonly assigned to five times limit of detection (LoD), is therefore 2 
mg/L, and the upper quantification limit is estimated as 200 mg/L to be within 20% precision 
range of the calibration curves.  
A set of spiked whole blood samples prepared for the accuracy and precision testing 
covered the range of CRP blood concentrations from 0.4 to 165 mg/L for the LiScAR. The 
sample set for the Alere Afinion was smaller, covering 5-150 mg/L CRP concentration range, 
appropriate for the measurement limits of the instrument.  
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Figure 4 The difference plots for the CRP assay measurement  and the nominal spiked CRP concentration in the whole blood 
media: (A) LiScAR (54 samples), and (B) Alere Afinion (37 samples) platforms; measured-nominal difference mean values 
are shown as solid lines with 95% CI as dashed lines 
The assay accuracy is assessed by the differences between the nominal volumetric 
concentrations and the assay measured concentrations. The difference plot demonstrating 
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the accuracy of the individual measurements for the LiScAR platform is shown in 






































































Figure 4A for the 54 tested blood samples, with a similar plot for the 37 measurements 
made with the Alere Afinion device in 







































































Figure 4B. The mean difference across the measured range of CRP concentrations for the 
LiScAR platform is -0.42 mg/L with 95% CI from -14.7 to 13.8 mg/L. The Alere Afinion 
measurements resulted in -4.63 mg/L mean difference with 95% CI from -22.7 to 13.4 mg/L. 
The negligible, -0.42 mg/L, mean measured-nominal [CRP] difference obtained for the 
LiScAR platform is expected since the instrument is calibrated using the same CRP stock 
material that was used in sample preparation. Correspondingly, a small bias of -4.63 mg/L in 
Alere measurement results can be attributed to a number of effects: a systematic under-
reading of CRP concentrations; errors associated with the purity of the CRP sample and 
hence the accuracy of the nominal CRP concentration of the stock solution; and 
uncertainties in the Alere Afinion calibration. A systematic under-read is more plausible 
from looking at the data 







































































Figure 4B: there is a noticeable dependence of the Alere result on [CRP], and the bias would 
not be observed if the sample range was limited to about 5-40 mg/L. 
 
Figure 5 Coefficient of variation for the precision across the sample concentrations with a minimum of two repeated 
measurement from  
The assay precision is characterised by Coefficient of Variation (CV) calculated as a 
standard deviation of the replicate at each concentration divided by the mean value for the 
repeated measurements and expressed as a percentage. The 95% CI for the CV are added to 
show the range expected with the current sample size, estimated using the method detailed 
30 elsewhere consider the uncertainty in the  standard error in the standard deviation and 
the standard error in the mean for a small sample.  Figure 5 shows the LiScAR and Alere 
Afinion precision data over the range of blood sample CRP concentrations. The average 
LiScAR assay precision has %CV of 10.6% with 95% CI 0.9% - 20.2% across the studied CRP 
concentration range. The analogous values for Alere Afinion are %CV of 12.3 with 95% CI 
2.0% - 22.7%. 
 
Discussion 
LiScAR is a multiplexed platform that can perform 8 assays per 150-spot array with up to 16 
repeats of each assay. In addition there are 16 reference spots to eliminate non-specific 
binding, temperature dependence and illumination variations.  The average array spot 
refractive index sensitivity is 310-5 RIU which compares with standard continuous surface 






























plasmon resonance sensitivities of 0.0310-5 RIU. The penetration depth of the plasmon 
field on the nanoparticle has however been recently measured as ca. 60 nm 16, indicating 
that the protein layer associated with the assay occupies a larger fraction of the plasmon 
field. Consequently, there is an intrinsic amplification or RI contrast ratio factor of 4.68 for 
the particles over the surface, reflected in the max 31. Fundamentally, plasmon sensors 
measure changes in local permittivity or refractive index which for protein sensors where 
the RI is constant, the biophotonics platforms are mass sensors. The mass of protein on the 
surface depends on the density of printed protein and the tethering efficiency which can be 
calibrated.  We have chosen the NIST reference material to calibrate the total antibody load 
onto the PAG surface. The maximum surface coverage is given by max = 7.35 ± 0.09 mRIU 
which may be compared with the random-close-packed antibody density. Assuming an 
antibody binding footprint of 91 nm2 RI conversion factor of 1 ng/mm2 ~1 mRIU 32 and 
plasmon field enhancement factor of 4.68 31, gives a maximum close-packed antibody 
density on the surface of 12.8 mRIU, suggesting 56% maximum antibody coverage is 
achieved in the presented experiments. The NIST-PAG surface coverage provides a very 
simple QC measure for the quality of the printed surface.  
For the CRP assay, the binding load of the aCRP polyclonal antibody is max = 2.95 ± 0.41 
mRIU, or 40% of NIST standard response, a variation that points to a sample integrity, purity 
and tethering efficiency. The latter may be due to fragmented antibodies binding to PAG: 
intact antibodies with full Fc biological activity, Fc-active fragments, either the Fc region 
completely fragmented from the Fab regions and so inactive biologically or Fc regions 
connected to one F(ab) region retaining some activity19. There may also be a differential 
binding affinity for PAG depending on the species from which the antibody has derived. We 
have explored the NIST-PAG calibration elsewhere19 comparing the plasmonic purity with an 
LCMS analysis of 5 antibodies in fragmentation from different host animals showing limited 
affinity variability but supporting the fragmentation proposition. NIST is similarly critical as a 
reference material in these experiments surviving the mass spectrometry launch process 
intact. The NIST antibody standard has a quoted monomeric purity of 96.6% intact 
antibodies 29 as confirmed by mass-spectrometric analysis. The F(ab) biological integrity is 
reflected in binding capacity of the printed capture aCRP antibodies having a max = (0.17 ± 
0.01) mRIU, correcting for the difference in mass of CRP and an antibody max-Ab equivalent = 
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(0.22 ± 0.01) mRIU, which in comparison with the NIST antibody standard load of 7.35 mRIU 
suggests that only just over 3% of surface available for antibody tethering is occupied by 
biologically active CRP capture antibodies in the correct orientation.  
The purity of the pAb capture antibody reducesthe sensor response by limiting the 
surface binding capacity of the CRP analyte and hence requires a complete set of QC 
parameters. The integrity of the surface can be interrogated by two QC assays: active Fab 
sites using the response to CRP and active Fc regions using the response to PAG. The 
average of max PAG binding aCRP surface is 0.10 ±0.02 mRIU and for CRP binding to the 
same aCRP surface gives 0.17 ± 0.01 mRIU, which correcting for the relative masses of PAG 
and CRP (50 kDa and 116 kDa) gives Fab = 49 ±11 % and Fc = 51 ±11 %. Once formed 
however, the CRP assay surface is remarkably robust allowing in excess of 100 repeat 
analyses and leading to good accuracy and precision measurements.  The average accuracy 
across the range CRP serum concentration range shows a mean difference of -0.42 mg/L 
(95% CI -14.7 to 13.8 mg/L) with precision of 10.6% (95% CI 0.9% - 20.2%) suggesting the 
current biophotonic platform has a clinically useful CRP range of 2 - 160 mg/L and an 
analysis time of eight minutes without any sample preparation.  
 The production properties of the assay are well defined in a set of QC parameters, 
such as surface protein loads and Fc presentation, suggesting that fabrication could be 
brought under process control with the correct supply of materials. The general FDA 
accuracy and precision requirements for a ligand-binding assay are met over the dynamic 
range of the CRP assay from the whole blood indicating that cells do not present a challenge 
for the surface. However, there are many remaining hurdles: matrix effects from different 
patients in particular with different lipids content, reliability of the sensor surfaces within 




The current biophotonic multiplexed platform has demonstrated sufficient accuracy and 
precision required for a clinically useful CRP assay. The technique offers a clinically useful 
triage assay for CRP range of 2 - 160 mg/L with an average accuracy of -0.42 mg/L (95% CI -
14.7 to 13.8 mg/L) and precision of precision of 10.6% (95% CI 0.9% - 20.2%) from a 5 L of 
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whole blood sample that requires no preparation and a result in 8 minutes. Critically, the 
integrity of the sensor surface can be interrogated with assays for surface protein density, 
Fc orientation and sample integrity parameterised against the NIST international standard 
material. These assay results provide a set of QC figures of merit that can easily be 
incorporated into in-line testing for batch production.  It is estimated that up to 60% of 
blood tests are not present in time to assist in the diagnosis 34 maybe we have a simple 
multiplex technology that can provide rapid triage diagnosis with clinical chemistry accuracy 
and precision.  
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